Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer

Trial Profile

Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Vinflunine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
    • 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date 1 Nov 2009 added as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top